Financial Consulate’s Vaxcyte PCVX Stock Holding History

Financial Consulate’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.5K	Hold	250	–	–	﹤0.01%	564
2025 Q4	$11.5K	Hold	250	–	–	﹤0.01%	587
2025 Q3	$9.01K	Buy	+250	New	+$8.28K	﹤0.01%	564

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Consulate's PCVX Position: Q1 2026 in Review

Financial Consulate held its Vaxcyte (PCVX) position steady in Q1 2026 at 250 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #564.

Financial Consulate first reported a position in PCVX in Q3 2025 and has held it in 3 quarters since. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Financial Consulate held 250 shares of Vaxcyte worth $14.5K as of Q1 2026.
Financial Consulate left its Vaxcyte share count unchanged in Q1 2026.
Vaxcyte made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #564 holding.
Financial Consulate first reported a position in Vaxcyte in Q3 2025 and has held it in 3 quarters since.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.